Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer
The triple combination of entinostat, a BETi, and cisplatin is highly synergistic, reverses cisplatin resistance, and may thus serve as a novel therapeutic approach for bladder cancer.
Authors
- Lukas M. Bollmann
- Linda Schäker‐Hübner (ORCID: https://orcid.org/0000-0001-7734-124X)
- Finn K. Hansen (ORCID: https://orcid.org/0000-0001-9765-5975)
- Alexandra Hamacher
- Matthias U. Kassack (ORCID: https://orcid.org/0000-0002-9094-8481)
- Friedrich Lange
- Lukas Biermann
Institutions
- University of Bonn (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-02
- DOI
- https://doi.org/10.3390/cancers16193374
- Citations
- 3
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.70